Mifobate
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD) -induced PPARγ transcriptional activity (IC50=140 μM) . Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR) . Mifobate (SR-202) shows antiobesity and antidiabetic effects[1].
Product Specifications
CAS Number
[76541-72-5]
Product Name Alternative
SR-202
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/mifobate.html
Purity
99.85
Solubility
H2O : 35.87 mg/mL (ultrasonic; warming) |DMSO : 100 mg/mL (ultrasonic)
Smiles
O=P(OC)(OC)OC(C1=CC=C(Cl)C=C1)P(OC)(OC)=O
Molecular Formula
C11H17ClO7P2
Molecular Weight
358.65
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARγ
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
